NanoPhoria
Biotechnology company developing non-viral nano-delivery systems for cardiovascular treatments, with a focus on inhalable biologics to enable new therapeutic approaches for heart disease.
Website
https://www.nanophoria.comLocation
Paris, France
Founded
2021
Investors
1
Categories
biotech, drug-delivery, cardiovascular, nano-medicine, inhalation
Notes
NanoPhoria is a biotechnology company pioneering non-viral nano-delivery systems for cardiovascular treatments. The company is developing innovative inhalable biologics that can deliver therapeutic proteins directly to the heart and cardiovascular system through pulmonary administration.
As a portfolio company of Sofinnova Partners, NanoPhoria is addressing the challenge of delivering large molecule therapeutics for cardiovascular diseases, which traditionally require invasive injection or infusion.
Team
- Information on leadership team pending further research
Additional Research Findings
- Founded around 2021
- Headquartered in Paris, France
- Portfolio company of Sofinnova Partners
- Non-viral nano-delivery platform
- Inhalable biologics for cardiovascular disease
- Novel administration route for heart therapies
- Addressing drug delivery challenges for large molecules
- French biotech ecosystem
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |